We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

63 hedge funds and large institutions have $15.6M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $791K | Put options by funds: $484K

7% less funds holding

Funds holding: 68 → 63 (-5)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

44% less capital invested

Capital invested by funds: $28M → $15.6M (-$12.4M)

75% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 16

Holders
63
Holders Change
-5
Holders Change %
-7.35%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
4
Reduced
16
Closed
16
Calls
$791K
Puts
$484K
Net Calls
+$307K
Net Calls Change
-$230K

Top Buyers

Rank Fund Capital Flow
1
MWM
Modera Wealth Management
New Jersey
+$792K
2
SFWC
Strategic Family Wealth Counselors
New Jersey
+$94.2K
3
Mariner
Mariner
Kansas
+$48.8K
4
BAM
Belpointe Asset Management
Nevada
+$45.3K
5
VF
Virtu Financial
New York
+$31.4K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$1.19M
2
Group One Trading
Group One Trading
Illinois
-$795K
3
WP
Woodline Partners
California
-$720K
4
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$478K
5
E
Ergoteles
New York
-$416K
Name Holding Trade Value Shares
Change 		Change in
Stake
CHA
51
Carmichael Hill & Associates
Maryland
$7.47K – – –
ACA
52
Aptus Capital Advisors
Alabama
$7.11K – – –
GWANC
53
Guardian Wealth Advisors (North Carolina)
North Carolina
$7.1K – – –
EWA
54
EP Wealth Advisors
California
$6.79K +$10.5K +3 New
UBS Group
55
UBS Group
Switzerland
$6.63K -$10.5K -3 -50%
Citadel Advisors
56
Citadel Advisors
Florida
$6.12K -$195K -56 -97%
NFSG
57
Newbridge Financial Services Group
Florida
$5.43K – – –
IA
58
IFP Advisors
Florida
$5K – – –
Fidelity Investments
59
Fidelity Investments
Massachusetts
$2.45K – – –
FIA
60
FNY Investment Advisers
New York
$2K – – –
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$2K – – –
HCM
62
Hollencrest Capital Management
California
$1.76K +$3.49K +1 New
Bank of America
63
Bank of America
North Carolina
$1.43K – – –
TWC
64
TD Waterhouse Canada
Ontario, Canada
$1.41K – – –
CG
65
Cutler Group
California
$1K -$3.49K -1 Closed
BC
66
Bartlett & Co
Ohio
$1K – – –
WIM
67
Westside Investment Management
California
$690 – – –
BCWM
68
Bartlett & Co Wealth Management
Ohio
$679 – – –
National Bank of Canada
69
National Bank of Canada
Quebec, Canada
$664 – – –
PA
70
Parallel Advisors
California
$576 – – –
FCA
71
FinTrust Capital Advisors
South Carolina
$340 – – –
PNC Financial Services Group
72
PNC Financial Services Group
Pennsylvania
$214 – – –
TWA
73
TCI Wealth Advisors
Arizona
$136 – – –
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$134 – – –
CA
75
CoreCap Advisors
Michigan
$68 – – –
1 2
3
4

SEEL Hedge Fund Activity: Q4 2022 in Review

63 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2022, worth a combined $15.6M — down 44% from $28M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SEEL and 11 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 4 added.

The largest buyer was Modera Wealth Management, opening a new position worth an estimated $792K. The largest seller was Uniplan Investment Counsel, cutting an estimated $1.19M.

  • 63 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2022, down from 68 in Q3 2022.
  • Funds reported $15.6M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2022, down 44% quarter-over-quarter.
  • 11 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2022 and 16 closed out, a net change of -5 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2022 was Modera Wealth Management, an estimated $792K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2022 was Uniplan Investment Counsel, an estimated $1.19M sold.

Based on aggregated 13F filings for Q4 2022.